A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils
Authors:
Open Access
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysisRespiratory Research, 2017
- A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitisEuropean Respiratory Journal, 2017
- Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialThe Lancet, 2016
- Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a studyThe Lancet Respiratory Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaNew England Journal of Medicine, 2014
- Minimum clinically important difference for the COPD Assessment Test: a prospective analysisThe Lancet Respiratory Medicine, 2014
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement2009
- Grading quality of evidence and strength of recommendationsBMJ, 2004
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001